Zydus Lifesciences Peer Comparison

NSE: ZYDUSLIFE | BSE: 532321

₹1,197.90

₹4.90 (0.41%)

As on 06-Nov-2026IST

Market cap

₹1,19,202 Cr

Revenue (TTM)

₹30,378 Cr

P/E Ratio

28.5

P/B Ratio

4.3

Div. Yield

0.1 %

Edit

	Zydus Lifesciences	Dr. Reddy'S Labs	Mankind Pharma	Aurobindo Pharma	Lupin
Market cap (₹ Cr)	1,19,202	1,14,532	1,04,913	1,03,395	91,001
Revenue (₹ Cr)	30,378	33,097	15,379	36,913	30,746
Net Profit (₹ Cr)	4,159.00	2,759.70	2,249.69	3,993.05	5,221.47
Net Margin (%)	13.20	8.03	14.32	10.61	16.70
RoE (%)	16.61	7.30	13.86	10.51	24.24
Price to Earnings	28.52	40.91	46.78	25.91	17.48
Price-To-Book	4.29	2.95	5.97	2.62	3.78

Income Statement (₹ Cr)

	Zydus Lifesciences	Dr. Reddy'S Labs	Mankind Pharma	Aurobindo Pharma	Lupin
Operating Revenue	30,378.10	33,097.40	15,378.58	36,912.88	30,746.33
Total Income	31,504.60	34,352.50	15,705.47	37,650.01	31,258.85
Total Expenditure	22,828.30	28,236.90	11,301.83	29,349.95	21,504.94
EBITDA	7,549.80	4,860.50	4,076.75	7,562.93	9,241.39
Depreciation	2,027.20	2,141.40	907.11	1,961.27	1,698.50
EBIT	5,522.60	2,719.10	3,169.64	5,601.66	7,542.89
Interest	595.90	450.40	513.87	394.85	450.49
Other Income	1,126.50	1,255.10	326.89	737.13	512.52
Exceptional Items	-499.30	0.00	-129.75	-105.51	-557.91
Profit before Tax	5,553.90	3,523.80	2,852.91	5,838.43	7,047.01
Provision for Tax	1,394.90	764.10	603.22	1,845.38	1,825.54
Profit after Tax	4,159.00	2,759.70	2,249.69	3,993.05	5,221.47

	Zydus Lifesciences	Dr. Reddy'S Labs	Mankind Pharma	Aurobindo Pharma	Lupin
Shareholder's Funds	27,817.30	38,807.00	17,582.22	39,399.90	24,050.46
Minority Interest	-101.90	40.20	-20.87	3.68	-15.31
Non-Current Liabilities	7,260.60	3,074.90	5,214.33	2,689.12	3,318.63
Current Liabilities	18,023.50	15,430.30	5,884.79	19,667.17	12,541.26
Total Liabilities	50,672.60	56,576.70	27,754.83	58,196.15	38,146.06

	Zydus Lifesciences	Dr. Reddy'S Labs	Mankind Pharma	Aurobindo Pharma	Lupin
Non-Current Assets	36,142.90	26,891.10	20,096.89	26,331.59	14,387.96
Current Assets	18,433.50	29,732.20	7,956.27	33,958.66	23,070.16
Total Assets	50,672.60	56,576.70	27,754.83	58,196.15	38,146.06
Total Debt*	11,769.50	7,734.10	6,021.78	7,676.20	5,910.20
Net Current Assets	410.00	14,301.90	2,071.48	14,291.49	10,528.90
Contingent Liabilities	989.90	336.14	924.77	1,358.37	1,094.02

	Zydus Lifesciences	Dr. Reddy'S Labs	Mankind Pharma	Aurobindo Pharma	Lupin
Cash From Operating Activities	2,116.60	5,673.70	3,121.29	5,526.37	7,334.50
Cash Flow from Investing Activities	-8,296.10	-6,549.30	-196.42	-3,458.61	-3,864.59
Cash from Financing Activities	5,806.90	829.00	-2,952.69	-1,269.15	-845.87
Net Cash Inflow / Outflow	-372.60	-46.60	-27.82	798.61	2,624.04

	Zydus Lifesciences	Dr. Reddy'S Labs	Mankind Pharma	Aurobindo Pharma	Lupin
ROCE (%)	21.39	13.75	13.24	12.76	28.86
ROE (%)	16.61	7.30	13.86	10.51	24.24
ROA (%)	8.11	4.93	7.79	6.99	14.23
EBIT Margin (%)	18.18	8.22	20.61	15.18	24.53
Net Margin (%)	13.20	8.03	14.32	10.61	16.70
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Zydus Lifesciences	Dr. Reddy'S Labs	Mankind Pharma	Aurobindo Pharma	Lupin
Revenue Growth (%)	24.02	-3.53	13.53	13.53	24.22
EBIT Growth (%)	-16.48	-58.47	31.59	13.09	38.02
Net Profit Growth (%)	-16.41	-51.77	27.79	15.82	20.10
EPS Growth (%)	-10.25	-51.50	34.22	19.29	30.16
Book Value Growth (%)	13.19	12.99	13.74	16.04	30.75

	Zydus Lifesciences	Dr. Reddy'S Labs	Mankind Pharma	Aurobindo Pharma	Lupin
Price / Earnings	26.26	40.88	44.66	25.56	16.14
Price / Book Value	4.29	2.95	5.97	2.62	3.78
Dividend Yield (%)	0.08	0.58	0.04	0.22	0.90
EV/EBITDA	16.39	23.71	26.72	13.28	9.49
Market Cap (₹ Cr)	87,643.18	1,04,763.81	82,801.75	75,689.14	1,05,737.27

	Zydus Lifesciences	Dr. Reddy'S Labs	Mankind Pharma	Aurobindo Pharma	Lupin
Debt to Equity	0.15	0.00	0.17	0.02	0.06
Short term debt to equity ratio	0.16	0.16	0.04	0.16	0.18
Current Ratio	1.02	1.93	1.35	1.73	1.84
Quick Ratio	0.64	1.40	0.95	1.06	1.32
Interest Coverage	10.32	8.82	6.55	15.79	16.64

	Zydus Lifesciences	Dr. Reddy'S Labs	Mankind Pharma	Aurobindo Pharma	Lupin
Debtors to sales (%)	14.42	30.64	14.17	20.44	21.65
Asset Turnover	0.59	0.59	0.53	0.65	0.84
Receivable days	33.55	103.79	39.93	33.71	51.23
Inventory Days	33.80	79.94	51.78	59.32	48.93
Payable days	149.82	84.78	111.46	148.20	205.75
Cash Conversion Cycle	-82.46	98.95	-19.75	-55.17	-105.59

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.